Skip to content

Precision Medicine in Hyperuricemia/Gout Management: An AI-Driven Clinical Trial

Precision Medicine in Hyperuricemia/Gout Management: An AI-Driven Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001283
Enrollment
Unknown
Registered
2026-05-26
Start date
2025-05-08
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Observation group:AI-augmented Traditional Chinese Medicine prescription (250 mL/dose BID p.o.) developed by rheumatologists

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Meet any one of the following conditions: 1) Serum uric acid (SUA) >480 µmol/L with at least one comorbidity (hypertension diabetes or hyperlipidemia); 2) Asymptomatic hyperuricemia with SUA >540 µmol/L; 3) Diagnosed with gout (based on 2015 ACR/EULAR classification criteria). (2) Aged 18-65 years (male or female). (3) No urate-lowering drugs used in the past 2 weeks. (4) Signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Severe cardiovascular endocrine digestive or hematologic diseases. (2) ALT >1.5× upper limit of normal (ULN) during screening. (3) eGFR <30 mL/min/1.73 m² during screening. (4) Pregnant/lactating women or individuals planning pregnancy (male/female). (5) Secondary gout caused by other diseases (e.g. tumor lysis syndrome). (6) Other conditions that may interfere with trial results (per investigators judgment).

Design outcomes

Primary

MeasureTime frame
Change in SUA levels from baselineFrequency of gout flares (acute attacks);

Secondary

MeasureTime frame
Change in Gout Outcome Measures (GOM) scale score;Metabolic and renal parameters: Blood pressure Blood glucose Lipid profile Serum creatinine Estimated glomerular filtration rate (eGFR);Variation in TCM syndrome score (per standardized TCM diagnostic criteria);Frequency of NSAID usage during treatment period;Proportion of patients achieving serum uric acid (SUA) <360 µmol/L at 12 weeks;Changes in inflammatory markers: C-reactive protein (CRP) Erythrocyte sedimentation rate (ESR) Pan-inflammatory indicators;The frequence of gout flares;

Countries

China

Contacts

Public ContactZhengdong Shen

Zhuhai Branch of Guangdong Provincial Hospital of Chinese Medicine

orientdong@163.com+86 185 1317 3077

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026